<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165736</url>
  </required_header>
  <id_info>
    <org_study_id>B3071001</org_study_id>
    <nct_id>NCT01165736</nct_id>
  </id_info>
  <brief_title>To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity</brief_title>
  <official_title>An Exploratory, Open Label, Randomized, Parallel Group Study To Investigate The Pharmacokinetics Of Single Intravenous And Oral Micro Doses Of PF-05186462, PF-05089771, PF-05241328 And PF-05150122 In Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to calculate the pharmacokinetics (concentration of compound in
      and rate of excretion from the blood) following a very low dose of compound which will not
      have any pharmacological activity and to monitor for the safety and tolerability of each of
      the compounds in the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (heart rate, blood pressure, QTcF, clinical chemistry)</measure>
    <time_frame>up to 3 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetics of each of the four compounds measuring Clearance, volume of distribution, elimination half life and area under the effect curve</measure>
    <time_frame>up to 3 days post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability of each of the four compounds (heart rate, blood pressure, QTcF, clinical chemistry)</measure>
    <time_frame>up to 3 days post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Intravenous: PF-05186462</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral: PF-05186462</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous: PF-05089771</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral: PF-05089771</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous: PF-05150122</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral: PF-05150122</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous: PF-05241328</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral: PF-05241328</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05186462</intervention_name>
    <description>single intravenous infusion of 100 microgram</description>
    <arm_group_label>Intravenous: PF-05186462</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05186462</intervention_name>
    <description>single oral administration of 100 microgram</description>
    <arm_group_label>Oral: PF-05186462</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05089771</intervention_name>
    <description>single intravenous infusion of 100 microgram of PF-05089771</description>
    <arm_group_label>Intravenous: PF-05089771</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05089771</intervention_name>
    <description>single oral administration of 100 microgram PF-05089771</description>
    <arm_group_label>Oral: PF-05089771</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05150122</intervention_name>
    <description>single intravenous administration of 100 microgram PF-05150122</description>
    <arm_group_label>Intravenous: PF-05150122</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05150122</intervention_name>
    <description>single oral administration of 100 microgram PF-05150122</description>
    <arm_group_label>Oral: PF-05150122</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05241328</intervention_name>
    <description>single intravenous infusion of 100 microgram PF-05241328</description>
    <arm_group_label>Intravenous: PF-05241328</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05241328</intervention_name>
    <description>single oral administration 100 microgram PF-05241328</description>
    <arm_group_label>Oral: PF-05241328</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male subjects between the ages of 18 and 50 years inclusive. (healthy is
             defined as no clinically relevant abnormalities identified by a detailed medical
             history, full physical examination including blood pressure and pulse rate
             measurement, 12-lead ECG and clinical laboratory tests)

          -  Body Mass Index (BMI) of 17.5 to 30.5kg/m2l and a total body weight of between 50 and
             100kg inclusive.

          -  Evidence of a personally signed and dated informed consent document indicating that
             the subject (or a legally acceptable representative) has been informed of all
             pertinent aspects of the trial.

        Exclusion Criteria:

          -  Evidence or history of clinically significant haematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, genitourinary, psychiatric, neurologic or
             allergic disease (including drug allergies, but excluding untreated, symptomatic,
             seasonal allergies at time of dosing)

          -  History of febrile illness within 5 days prior to the first dose a positive urine drug
             screen
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH14 4AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3071001&amp;StudyName=To%20calculate%20the%20pharmacokinetics%20%28concentration%20of%20compound%20in%20and%20rate%20of%20excretion%20from%20the%20blood%29%20following%20a%20very%20low%20dose%20of</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2010</study_first_submitted>
  <study_first_submitted_qc>July 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2010</study_first_posted>
  <last_update_submitted>August 23, 2010</last_update_submitted>
  <last_update_submitted_qc>August 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>Chronic Pain</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

